您现在的位置: 首页   -  产品中心   -  免疫学   -   抗体
B7-1/CD80 His Tag Protein, Human

B7-1/CD80 His Tag Protein, Human

货号: UA010085
价格: 2340
规格: 100μg
介绍: -
其他: -
产品规格
  • 物种

    Human
  • Accession

    P33681-1
  • 表达序列

    Val35-Asn242, with C-terminal 10*His VIHVTKEVKEVATLSCGHNVSVEELAQTRIYWQKEKKMVLTMMSGDMNIWPEYKNRTIFDITNNLSIVILALRPSDEGTYECVVLKYEKDAFKREHLAEVTLSVKADFPTPSISDFEIPTSNIRRIICSTSGGFPEPHLSWLENGEELNAINTTVSQDPETELYAVSSKLDFNMTTNHSFMCLIKYGHLRVNQTFNWNTTKQEHFPDNGGGSHHHHHHHHHH
  • 表达宿主

    HEK293
  • 分子量

    43-55kDa (Reducing)
  • 纯度

    >95% by SDS-PAGE

  • 内毒素含量

    <0.1EU/μg
  • 标记

    Unconjugated
  • 标签

    His Tag
  • 性状

    Lyophilized Powder
  • 缓冲体系

    PBS, pH7.4
  • 溶解方法

    Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
  • 储存条件

    · 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
    · 3 months, -20 to -80℃ under sterile conditions after reconstitution.
    · 1 week, 2 to 8℃ under sterile conditions after reconstitution.
    · Please avoid repeated freeze-thaw cycles.
  • 稀释度

背景介绍
  • As the first identified B7 family member, CD80 is widely expressed in a broad spectrum of tissues, even on some malignant tumor cells, thereby suggesting the potential mechanism of immune evasion of tumor cells.CD80 is recognized as one of the most potent costimulatory molecules by which immune cells limit malignant growth. It is upregulated upon cell stress and it is critical for efficacious immune surveillance during carcinogenesis. Low surface expression of CD80 was reported as an immune escape mechanism of colon carcinoma; on the other hand, its expression resulted enhanced in high-frequency microsatellite instability (MSI) colorectal cancers, a CRC subtype which is highly immunogenic and associated with a better prognosis. Both in vivo and in vitro studies showed that the upregulation of CD80 on tumor cell surface successfully activates antitumor immune responses, while its expression is frequently lost during tumor progression probably due to selective pressure by the immune system. Thus, to develop effective approaches for cancer immunotherapy, strategies for enhancing CD80 expression in tumors are urgently required.

  • 生物活性JSON

    • Anti-His antibody Immobilized on CM5 Chip captured B7-1/CD80 His Tag, Human (Cat. No. UA010085), can bind CTLA-4 Fc Chimera, Human (Cat. No. UA010039) with an affinity constant of 8.432nM as determined in SPR assay (Biacore T200).
    • Immobilized B7-1/CD80 His Tag, Human (Cat. No. UA010085) at 5μg/mL (100μL/well) can bind CTLA-4 Fc Chimera, Human (Cat. No. UA010039) with EC50 of 85.96ng/mL.
  • 电泳JSON

    • 1μg(R: reducing conditions, N: non-reducing conditions).